Precision Medicine
5 Early-Stage Precision Medicine Startups Matching Treatment to Biology
DealBio tracks early-stage precision medicine startups across Europe and North America. These 5 are matching treatment decisions, trial selection or therapeutic design more closely to patient biology.
- Biotech
- Diagnostics
- Oncology
- Fertility
- Rare Disease
- Cell Therapy
Precision medicine becomes commercially meaningful when biological differences change a real decision: which patient enters a trial, which treatment is prescribed, which target is pursued or how a therapy is designed. The opportunity is therefore broader than genetic testing alone. It includes diagnostics, molecular data platforms and therapies built around defined biological subgroups.
The five startups below operate in very different markets, but share the same thesis. Each is narrowing a clinical or development decision around information that is more specific than the disease label itself, from RNA and genotype to tumor neoantigens, genetically defined syndromes and targeted immune-cell programs.
At a Glance
- Blank BioUnited States2025RNA-based trial patient selection
- Dx4LifeSweden2024Genotype-guided IVF hormone selection
- Nema HealthSpain2024Personalized neoantigen immunotherapy
- Translation-XSwitzerland2026Therapy for genetically defined autism
- Circle BioNetherlands2024Tailored CAR-T for autoimmune disease
Training RNA foundation models to guide oncology trial patient selection.
- Country
United States- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Blank Bio stands out
Blank Bio has paired a $7.2 million oversubscribed seed round with a collaboration with PacBio to generate long-read RNA-sequencing data from up to 100 patient tumor samples across multiple cancer indications at Seattle Children's Research Institute. Its underlying Orthrus RNA foundation model was published in Nature Methods in 2026.
The founding team combines RNA biology, machine learning and oncology experience, and the startup was selected for Y Combinator's Summer 2025 batch. That gives Blank Bio both a scientific model-development base and a defined clinical-development use case.
What Blank Bio is building
Blank Bio is building RNA foundation models for oncology clinical development. The platform analyses RNA-sequencing data to help pharmaceutical and diagnostic teams predict treatment response, assess disease progression and improve existing molecular tests.
Its three clinical applications are predictive biomarkers for treatment response, prognostic scores for disease progression and diagnostic partnerships that improve existing RNA-sequencing tests. The platform is designed to work with bulk RNA-sequencing data already generated in oncology research and clinical development.
Investment Perspective
The strongest signal is the combination of proprietary model development, peer-reviewed validation and access to new tumor RNA data through the PacBio collaboration. The investment question is whether that technical advantage can translate into better patient-selection and biomarker decisions inside expensive oncology trials, creating value without requiring customers to change how samples are collected or sequenced.
02
Dx4Life
Developing a rapid swab test to match IVF hormone treatment to a woman's genetics.
- Country
Sweden- Founded
- 2024
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Dx4Life stands out
Dx4Life has raised SEK 6.4 million in its first funding round, filed for international patent protection and emerged from ReproUnion before joining SmiLe Venture Hub. Founder Yvonne Lundberg Giwercman is a professor at Lund University and has led research in reproductive genetics for more than a decade.
The clinical evidence is unusually direct for an early diagnostic. A peer-reviewed study of 1,466 women found a 40% cumulative live-birth rate when treatment matched genotype, compared with 29% among non-genotyped controls. Dx4IVF also agreed with DNA sequencing in 91 of 100 patient samples.
What Dx4Life is building
Dx4Life is developing Dx4IVF, a point-of-care genotyping test for fertility clinics. A cheek swab identifies an FSH-receptor variant associated with different responses to ovarian-stimulation hormones and returns a visible result in under an hour.
The test is designed to guide hormone selection before IVF begins. Because fertility clinics already control the prescribing decision, the genetic result can be used during the existing appointment rather than creating a separate testing pathway.
Investment Perspective
Dx4Life's differentiation sits in decision timing and workflow fit: it brings a genetic result into the clinic before treatment is selected. The peer-reviewed outcome data, rapid readout and patent strategy support the case, while the commercial milestone is whether clinics adopt genotype-guided prescribing as a routine step in IVF.
Developing a personalized neoantigen immunotherapy for advanced melanoma.
- Country
Spain- Founded
- 2024
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Nema Health stands out
Nema Health raised a €730,000 seed round led by BCN Peptides, alongside a separate €335,000 NEOTEC grant. It holds an exclusive licence to DIF peptide patents granted across six jurisdictions from Universitat de Lleida, Vall d'Hebron Research Institute and IRBLleida.
CEO Olga Rué Clarós previously led vaccine developer Archivel Farma for more than a decade, including clinical development of its RUTI tuberculosis vaccine. That operating history adds development and financing experience to a personalized immunotherapy program that remains preclinical.
What Nema Health is building
Nema Health is developing OncoNeoVac for advanced melanoma. The therapy combines patient-specific tumor neoantigens with DIF peptides derived from peripherin, using individualized tumor targets while the DIF peptides act as an immune-stimulating adjuvant.
The initial focus is stage III and IV melanoma in patients whose cancer does not respond to checkpoint inhibitors or later relapses. Nema Health plans to build the preclinical evidence package internally and then out-license the program for later-stage development and commercialization.
Investment Perspective
Nema Health's investment case combines personalized target selection with a defined partnering model. The granted patent family, exclusive licence, seed financing and CEO's prior vaccine-development experience strengthen the platform around its lead melanoma program; the next value step depends on converting that foundation into a sufficiently strong preclinical package for pharmaceutical partnering.
Developing oral small molecules for core symptoms of genetically defined autism.
- Country
Switzerland- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Translation-X stands out
Translation-X is built around genetically defined autism syndromes, where the patient population and underlying biology can be specified more tightly. Research from University of Basel published in Nature showed that MNK1/2 inhibition restored oxytocin signalling and social behaviour in a genetic autism mouse model.
The startup has raised CHF 1 million across non-dilutive grants and equity funding. Co-founder Guido Koch brings more than 25 years of pharmaceutical R&D experience, including 22 years at Novartis and contributions to two marketed drugs and seven clinical candidates.
What Translation-X is building
Translation-X is developing brain-penetrant oral small molecules that selectively inhibit MNK1/2, enzymes involved in regulating protein production in cells. The compounds are designed to rebalance abnormal protein production in neurons.
Initial programs focus on Fragile X syndrome, Phelan-McDermid syndrome and tuberous sclerosis complex. Starting with genetically defined conditions gives the startup a narrower biological hypothesis and a more clearly specified early patient population than broad autism drug development.
Investment Perspective
Translation-X combines a mechanism-led patient strategy with target validation and experienced drug-development leadership. The defined genetic syndromes can sharpen early development, while the Nature-published biology and chemistry experience reduce some of the uncertainty around target and molecule design. The central execution question is whether that preclinical rationale translates into a development candidate with a credible path into patients.
Developing tailored CAR-T therapies for rheumatoid arthritis and multiple sclerosis.
- Country
Netherlands- Founded
- 2024
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Circle Bio stands out
Circle Bio is led by repeat founders Maarten Zandvliet and Tol Trimborn, who previously co-founded CellPoint. Galapagos acquired CellPoint for €125 million upfront plus up to €100 million in milestone payments, and the founders helped take its CAR-T platform into two Phase 1/2a studies.
Circle Bio's live DealBio brief names rheumatoid arthritis and multiple sclerosis as its current autoimmune CAR-T programs and describes an autologous platform using two validated targets, mild conditioning and a simplified treatment workflow.
What Circle Bio is building
Circle Bio is developing autologous CAR-T therapies for rheumatoid arthritis and multiple sclerosis. The platform uses a patient's own T cells and combines two validated targets with mild conditioning, lean automated processing and a digitally driven workflow.
The therapeutic goal is an immune reset that can produce deeper, treatment-free remission while reducing the intensity and logistical burden associated with conventional CAR-T treatment. The platform also includes novel targets intended to extend the approach into major autoimmune indications.
Investment Perspective
Circle Bio's strongest signal is founder execution history in CAR-T, including a prior acquisition and clinical-stage development. That experience is directly relevant to manufacturing, clinical operations and partnering in a complex cell-therapy category. The investment case now depends on whether the tailored autoimmune programs can preserve CAR-T's depth of response while simplifying conditioning and treatment logistics.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
Precision medicine is often discussed as a single category, but these startups show several distinct business models. Blank Bio and Dx4Life improve decisions around existing clinical workflows; Nema Health and Translation-X define therapies around narrower biological patient groups; Circle Bio applies targeted cell therapy to diseases where treatment is usually chronic rather than curative.
For investors, the useful question is not simply whether a startup is personalized. It is whether the biological signal changes a valuable decision and whether that decision sits inside a workable development or commercial pathway. Evidence quality, access to the right data or patients, IP, workflow fit and the team's ability to execute in the relevant modality become more important as the target population narrows.
Methodology
DealBio selected these five early-stage startups because each uses patient biology to make treatment selection, clinical-development decisions or therapeutic design more specific. The selection spans RNA-based oncology tools, fertility genotyping, personalized cancer immunotherapy, genetically defined neurodevelopmental disease and targeted autoimmune cell therapy.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.